The effect of lipid composition on the intracellular antibacterial activity of ampicillin-containing liposomes was studied in vitro by using mouse peritoneal macrophages infected with Listeria monocytogenes. Two types of liposomes, a fluid type, consisting of cholesterol-phosphatidylcholine-phosphatidylserine (5:4:1), and a solid type, consisting of cholesterol-distearoylphosphatidylcholine-dipalmitoylphosphatidylglycerol (10:10:1), were used. Although the cellular uptake of both types of liposomes was similar, they differed with respect to the rate of intracellular degradation. A 
The effect of lipid composition on the intracellular antibacterial activity of ampicillin-containing liposomes was studied in vitro by using mouse peritoneal macrophages infected with Listeria monocytogenes. Two types of liposomes, a fluid type, consisting of cholesterol-phosphatidylcholine-phosphatidylserine (5:4:1), and a solid type, consisting of cholesterol-distearoylphosphatidylcholine-dipalmitoylphosphatidylglycerol (10:10:1), were used. Although the cellular uptake of both types of liposomes was similar, they differed with respect to the rate of intracellular degradation. A correlation was found between the relatively slow degradation of the solid liposomes and a delayed intracellular release of the encapsulated ampicillin, as reflected in absent or delayed intracellular killing of L. monocytogenes.
The use of liposomes as carriers of therapeutic agents has been extensively studied. Investigations of the delivery of antitumor or antimicrobial agents by means of liposomes were performed with experimental models of tumors or infectious disease (3, 7, 10) . Liposomal delivery of antimicrobial agents has been demonstrated in models of the intracellular parasitic infections leishmaniasis and malaria; of mycotic infections such as histoplasmosis, cryptococcosis, and candidiasis; and of infection caused by Rift Valley fever virus (4) . The effect of liposomal encapsulation on the therapeutic activity of antibacterial agents against experimental intracellular bacterial infections caused by Mycobacterium tuberculosis, Legionella pneumophila, Salmonella enteritidis, or Brucella abortus was studied (4) . The animal studies demonstrated an improved therapeutic index and reduced toxicity resulting from encapsulation of the drugs within liposomes.
Targeting of antimicrobial agents by means of liposomes may be of great value in the treatment of intra-or extracellular infections that prove refractory to conventional forms of antimicrobial therapy. Lopez-Berestein et al. demonstrated in a clinical study that liposome-entrapped amphotericin B was beneficial in the treatment of fungal infections in a number of leukopenic cancer patients who had been unsuccessfully treated with the nonencapsulated drug (9) . Selection of the appropriate liposome carrier system for drug delivery in vivo requires better understanding of the mechanisms responsible for the increase in therapeutic effect resulting from liposomal encapsulation of the drug.
Numerous studies demonstrate that liposomes are effectively phagocytosed by macrophages both in vivo and in vitro (11) . It has also become apparent that both the extent of uptake and the rate of intracellular degradation of liposomes by macrophages are decisive in determining the rate at which a liposome-encapsulated drug becomes available, either intracellularly or extracellularly, and hence the therapeutic efficacy (12) . In previous in vivo and in vitro studies, we demonstrated that liposomal encapsulation of ampicillin resulted in an increased availability of the antibiotic for the intracellular bacterium Listeria monocytogenes in murine macrophages (1, 2 Control suspensions were incubated without ampicillin. At the times indicated during the period of reincubation, the monolayers were washed three times with PBS at 0C, and the macrophages were disrupted by being quickly frozen and thawed in the presence of distilled water containing 0.01% bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.), 0.1% Triton X-100 (BDH, Poole, England), and 10 U of penicillinase SR 106 (Oxoid) per ml. Triton X-100 was added to disrupt the ingested liposomes. Penicillinase was added for immediate inactivation of ampicillin released after disruption of cells and liposomes. Suspensions were mixed vigorously. Freezing and thawing did not affect the viability of L. monocytogenes. The intracellular numbers of viable bacteria were determined by preparing 10-fold serial dilutions and performing subcultures on blood-agar plates. In addition, the intracellular numbers of radioactively labeled bacteria were determined.
Liposomes. Cholesterol, egg phosphatidylcholine (PC) and L-ot-phosphatidyl-L-serine (PS) were obtained from Sigma. L-a-distearoylphosphatidylcholine (DSPC) and L-ox-dipalmitoylphosphatidylglycerol (DPPG) were obtained from Avanti, Birmingham, Ala. Liposome preparations were multilamellar vesicles consisting of either cholesterol-PC-PS in a molar ratio 5:4:1 (fluid liposomes) or cholesterol-DSPC-DPPG in a molar ratio of 10:10:1 (solid liposomes). Liposomes were sized by extrusion through polycarbonate filters (no. 94566 [final pore size, 0.4 ,um]; Nuclepore Corp., Pleasanton, Calif.) and freed of nonentrapped ampicillin on a Sephadex G-100 column (Pharmacia, Uppsala, Sweden). Liposomes were prepared essentially as described previously (1), with some modifications for the cholesterol-DSPC-DPPG liposomes: because of the high transition temperature of the DSPC used (58°C), these liposomes were prepared at 62°C. For determnination of ' The cellular uptake and intracellular survival of L. monocytogenes at different time intervals during the periods of uptake and reincubation in the absence of liposomeentrapped ampicillin are shown in Fig. 3 . From the start of incubation of the macrophages and L. monocytogenes (T = -30 min), a gradual uptake of bacteria was measured in terms of viable bacteria as well as radioactively labeled bacteria, resulting in 5 x 106 L. monocytogenes organisms per 106 macrophages after the 30-min uptake period. After removal of the noningested bacteria, during the first hour of incubation the number of 'intracellular bacteria did not change. After that time intracellular bacterial multiplication occurred up to threefold within 4 h of incubation and up to sixfold within 6 h. Owing to the' intracellular multiplication of L. monocytogenes, gradual lysis of the infected macrophages occurred during the last 2 h of incubation, as reflected by a slow release of radioactivity from the cells.
Effect of liposome-entrapped ampicillin on intracellular survival of L. monocytogenes. After removal of the noningested bacteria at the end of the uptake period, macrophages were reincubated in the presence of 25 or 50 ,ug of ampicillin encapsulated'in one of the two types of liposomes (Fig. 4) . In the presence of 25 pug of ampicillin per ml encapsulated in cholesterol-PC-PS (5:4:1) liposomes, the number of intracellular bacteria did not change during the first 3 h, but after 6 h of incubation 90% of the intracellular bacteria were killed.
The delay in intracellular killing is probably due partly to the degradation time of the liposomes and release of ampicillin and partly to binding of ampicillin to penicillin-binding proteins PBP's of the bacteria. The decrease in the number of intracellular bacteria as measured was not due to lysis of infected macrophages, since the number of intracellular radioactively labeled bacteria remained constant during the Macrophages in monolayer culture were exposed to radioactively labeled L. monocytogenes for 30 min. Then (zero time) the noningested bacteria were removed, and the macrophages were reincubated for 6 h. At the times indicated during the periods of uptake and reincubation, the macrophages were disrupted and the number of intracellular viable bacteria, as well as the cell-associated radioactivity, was determined. Data are mean values ± standard errors of the mean for three determinations. period of incubation (data not shown). However, when encapsulated in cholesterol-DSPC-DPPG (10:10:1) liposomes, 25 pLg of ampicillin per ml did not result in intracellular bacterial killing: although multiplication of intracellular bacteria was significantly lower than in the controls, the bacteria multiplied up to threefold within 6 h. As shown for both types of liposomes, the presence of 25 pig of free ampicillin plus empty liposomes had no significant effect on the intracellular bacterial multiplication. Doubling the amount of ampicillin encapsulated in cholesterol-PC-PS liposomes to 50 pg/inl led to a rapid killing of almost all (97%) of the intracellular bacteria. In contrast, when 50 ,ug of ampicillin was encapsulated in cholesterol-DSPC-DPPG liposomes, intracellular killing was delayed and less effective: only 70% of the intracellular bacteria were killed after 6 h. As shown for both types of liposomes, 50 ,ug of free ampicillin plus empty liposomes only inhibited intracellular bacterial multiplication but did not kill the bacteria.
DISCUSSION
In previous studies of experimental L. monocytogenes infection in mice, we observed a considerable enhancement (90-fold) in the therapeutic activity of ampicillin resulting from liposomal encapsulation (1) . The mechanism by Which liposomes improved the therapeutic index of ampicillin in this infection appeared to be an increased delivery of the antibiotic to the site of infection, i.e., the liver and spleen. In addition, in studies of the survival of L. monocytogenes in vitro within murine peritoneal macrophages after in vivo phagocytosis of the bacteria, we found that liposomal encapsulation of ampicillin resulted in an increased availability of the antibiotic for the intracellular bacteria: liposomal ampicillin killed 99% of the intracellular bacteria, whereas a similar concentration of free ampicillin plus empty liposomes had no antibacterial effect (2) . These results are in line with observations made by several other investigators demonstrating in vitro the superiority of liposome-entrapped antibiotics over nonentrapped antibiotics in effecting killing of intracellular bacteria. They demonstrated that intracellular killing of Staphylococcus aureus in canine monocytes or mouse peritoneal macrophages by aminoglycosides or dihydrostreptomycin, of Escherichia coli in a macrophage cell line by streptomycin and chloramphenicol, and of Salmonella typhimurium in peritoneal mouse macrophages by cephalothin was enhanced by encapsulating the drugs within liposomes (5, 6, 8, 13) .
In the present study we examined the effect of free versus liposome-encapsulated ampicillin on the survival of L. monocytogenes in murine peritoneal macrophages after phagocytosis in vitro. We used two types of liposomes, both of which were multilamellar vesicles with a mean diameter of ca. 0.4 .m but which differed in the lipid composition of the liposomal membranes, resulting in a difference in membrane fluidity. We used liposomes composed of cholesterol, DSPC, and DPPG, a solid liposome type owing to the presence of saturated phospholipids with high transition temperatures (above 37°C). The fluid liposome type was composed of cholesterol, PC, and PS, which have transition temperatures well below 37°C. The uptake of both types of liposomes by peritoneal macrophages in monolayer culture in vitro was found to be similar. However, the rate of intracellular degradation appeared to be dependent on the lipid compcsition: the solid liposomes were degraded relatively slowly as compared with the fluid liposomnes. The differences in degradation rate of the two types of liposomes correlated with the rate at which the encapsulated antimicrobial drug was released intracellularly as measured by differences in onset of killing of L. monocytogenes intracellularly by ampicillin.
Encapsulation of ampicillin at a concentration of 50 jig/ml in vesicles of the solid liposome type as compared with the fluid liposome type resulted in delay of intracellular killing of L. monocytogenes. At an ampicillin concentration of 25 jig/ml, intracellular bacterial killing was absent when ampicillin was encapsulated in the solid liposome type; however, when encapsulated in the fluid liposomes, ampicillin was still bactericidal at that concentration. Similar results were obtained by Storm et al. (14) , who found in an experimental tumor model that the expression of antitumor activity induced by doxorubicin-containing liposomes in vivo varied with the lipid composition of the liposomes. Using doubleradiolabeled liposomes, they obtained evidence that the degradation rate of the vesicles after uptake by macrophages was dependent on the lipid composition of the bilayers. Solid liposomes, by virtue of the highly packed acyl chains in the lipid membranes, are less susceptible to lysosomal enzyme activities than are fluid liposomes, causing a delay in liposomal degradation after uptake of the vesicles by macrophages. Slow degradation of the solid liposome type resulted in retarded onset of tumor regression, apparently induced by doxorubicin released from the macrophages. In this respect, the macrophages serve as depot cells from which the drug is released over a prolonged period. These results could recently be confirmed by using liver macrophages in maintenance culture: after uptake of doxorubicin-containing solid liposomes, a delayed release of the drug was observed in the culture medium as estimated by high-performance liquid chromatography (G. Storm, Ph.D. thesis, State University of Utrecht, Utrecht, The Netherlands, 1987).
In conclusion, evidence is presented that intracellular processing of the liposomes seems to be an important determinant for the intracellular release and hence the therapeutic effect of the encapsulated drug. By varying the lipid composition of the liposomes, it is possible to manipulate the rate of intracellular degradation and hence the therapeutic availability of the encapsulated agent. More studies are needed to establish the optimal liposomal lipid composition for delivery of agents in vivo in experimental infection models.
